Clinical Trial

Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer

Study acronym: PELICAN
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase II multicentre randomized open-label study will assess the safety and efficacy of Pembrolizumab in combination with standard chemotherapy in inflammatory breast cancer. Pembrolizumab will be administered every 3 weeks during the neoadjuvant chemotherapy. Tissue and blood samples will be collected pre- and post-treatment for translational research.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2018-05-03; most recent amendment 2025-11-17.
Status change: Recruiting → Active, Not Recruiting 2024-07-25
Status change: Not Yet Recruiting → Recruiting 2019-05-06
Trial Details
NCT Number NCT03515798
Lead Sponsor Institut Paoli-Calmettes
Collaborators: MSD France, Oncodistinct
Conditions Inflammatory Breast Cancer
Enrollment 52 participants
Start Date 2018-08-29
Primary Completion 2022-08-22 (estimated)
Study Completion 2027-08-22 (estimated)
Updated on ClinicalTrials.gov 2025-09-12